Gensco® Leadership Team
Gensco® is a specialty pharmaceutical manufacturer specializing in development and commercialization of prescription topically-applied transdermal products. Our capabilities allow us to quickly launch products into significant niche markets. Our Leadership Team oversees organizational goals, strategic planning development, and overall decision making.
Medical Advisory Board
We currently have relationships with key medical advisors including:
James R. Andrews, MD
Orthopedic Surgeon Andrews Sports Medicine and Orthopedic Medicine.
Gary E. Myerson, MD
Rheumatologist Arthritis & Rheumatology Georgia, P.C.
Alesia Wagner, DO, FACOFP
Associate Professor, Primary Care Touro University College of Osteopathic Medicine
Marc Alan Brenner, DPM
Podiatrist The Institute for Diabetic Foot Research
Gensco® Pharma is committed to Better Science for Health.
Our resources are focused on innovative research, the development of superior quality medications and unique delivery systems. We are an evidence-based solutions company that is progressively developing products utilizing new technologies that deliver outcomes to reduce the effects caused by disease or pathology.
Looking To The Future
- Physician Explores Gout Treatment Options May 15, 2017 Articles, Clinical, Featured - As seen in Chain Drug Review | May 15, 2017 MIAMI — Gout is an extremely painful form more...
- The Difference Between Topical and Transdermal Medications March 29, 2017 Clinical, Research - White Paper by Robert L. Wilbur, Pharm.D., CPh | Executive Director, Medical Affairs, Gensco Pharma Abstract more...
- Working In All Disease States and Cost Management Areas to Help Patients Access Medications March 21, 2017 Clinical, Featured, Industry - Gensco® President and CEO, Carlos Alfaras, recently moderated a Thought Interaction Pod (TIP) session at more...
- Advances in Treatment of Painful Wounds November 28, 2016 Articles, Clinical, Featured - by Marc Alan Brenner, DPM, The Institute for Diabetic Foot Research As seen in Podiatry Management more...